Federation Des Caisses Desjardins Du Quebec Liminal Bio Sciences Inc. Transaction History

Federation Des Caisses Desjardins Du Quebec

$18.9 Billion
Q3 2024

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 Aug 14, 2024	SELL	$0.33 - $5.72 $10,675 - $185,036	-32,349 Closed	0 $0
Q4 2022 Aug 14, 2024	SELL	$0.32 - $0.5 $1,491 - $2,330	-4,661 Reduced 12.59%	32,349 $10.5 Million
Q3 2022 Aug 14, 2024	SELL	$0.4 - $0.59 $76 - $112	-191 Reduced 0.51%	37,010 $15.5 Million
Q2 2022 Aug 14, 2024	SELL	$0.44 - $0.97 $90 - $199	-206 Reduced 0.55%	37,201 $19.1 Million
Q1 2022 Aug 14, 2024	BUY	$0.82 - $1.13 $30,673 - $42,269	37,407 New	37,407 $37 Million
Q4 2021 Aug 30, 2024	SELL	$0.92 - $2.2 $8,048 - $19,245	-8,748 Reduced 18.71%	38,013 $41.4 Million
Q3 2021 Aug 30, 2024	SELL	$2.15 - $3.92 $926 - $1,689	-431 Reduced 0.91%	46,761 $108 Million
Q2 2021 Aug 30, 2024	BUY	$3.75 - $5.17 $176,970 - $243,982	47,192 New	47,192 $184 Million
Q1 2021 Aug 30, 2024	BUY	$3.94 - $6.43 $22,158 - $36,162	5,624 Added 12.57%	50,359 $208 Million
Q4 2020 Aug 30, 2024	BUY	$3.68 - $11.02 $20,534 - $61,491	5,580 Added 14.25%	44,735 $188 Million
Q3 2020 Aug 30, 2024	SELL	$10.51 - $23.79 $8,744 - $19,793	-832 Reduced 2.08%	39,155 $436 Million
Q2 2020 Aug 30, 2024	BUY	$6.3 - $11.35 $926 - $1,668	147 Added 0.37%	39,987 $415 Million
Q1 2020 Aug 30, 2024	SELL	$5.4 - $12.93 $8,661 - $20,739	-1,604 Reduced 3.87%	39,840 $251 Million
Q4 2019 Aug 30, 2024	BUY	$5.47 - $11.33 $226,698 - $469,560	41,444 New	41,444 $336 Million

Others Institutions Holding LMNL

# of Institutions

Shares Held

234

Call Options Held

Put Options Held

View Full List

About Liminal BioSciences Inc.

Ticker LMNL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 31,042,600
Description
Liminal BioSciences Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel small molecule drug therapeutics for inflammatory, fibrotic, and metabolic diseases in Canada and the United Kingdom. The company's lead product candidate is fezagepras (PBI-4050), which has been completed Phase I clinical trial for the trea...

More about LMNL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Federation Des Caisses Desjardins Du Quebec, based on Form 13F filings with the SEC.

News

Stay updated on Federation Des Caisses Desjardins Du Quebec with notifications on news.

Account